Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CRHBP | P24387 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.45 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | CCR9 | P51686 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10222598 | 0.83 | CCR9 (0.49) | MAPTALDH1A1HPGDLMNACRHBP | |
| SCHEMBL28596 | 0.83 | BDKRB1 (0.63) | ALDH1A1HPGDLMNAHTTKDM4E | |
| SCHEMBL27705 | 0.80 | BDKRB1 (0.50) | MAPTALDH1A1HPGDLMNACRHBP | |
| SCHEMBL28717 | 0.80 | CCR9 (0.50) | MAPTALDH1A1HPGDLMNACRHBP | |
| SCHEMBL10223159 | 0.76 | CCR2 (0.59) | LMNAKDM4ESLC40A1MEN1KMT2A | |
| SCHEMBL12359434 | 0.76 | LMNA (0.64) | MAPTALDH1A1HPGDLMNAHTT | |
| SCHEMBL27168 | 0.75 | CCR9 (0.56) | MAPTALDH1A1HPGDLMNACRHBP | |
| SCHEMBL27486 | 0.75 | LMNA (0.72) | MAPTLMNAHTTKMT2ATP53 | |
| SCHEMBL10223655 | 0.75 | CCR9 (0.57) | MAPTLMNABDKRB1CCR9RAB9A | |
| SCHEMBL13077856 | 0.74 | FFAR4 (0.50) | MAPTALDH1A1HPGDLMNACRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402310-A1 | CCR9 inhibitors and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | claimed |
| EP-2399903-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | claimed |
| US-20100324093-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | claimed |
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | claimed |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | claimed |
| EP-1507756-A4 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2006-03-15 | — | — | EP | claimed |
| JP-2005526857-A | — | — | 2005-09-08 | — | — | JP | claimed |
| EP-1507756-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| WO-2003099773-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CHEMOCENTRYX, INC. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | disclosed |
| WO-2006076644-A2 | HETEROARYL SULFONAMIDES AND CCR2 | CHEMOCENTRYX, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
| EP-1507756-A4 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1507756-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003099773-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11433061-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPT 4586/4885ALDH1A1 2834/4885HPGD 2694/4885 |
| US-10206912-B2 | Heteroaryl sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPT 4586/4885ALDH1A1 2834/4885HPGD 2694/4885 |
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | MAPT 2968/4885ALDH1A1 2607/4885HPGD 3695/4885 |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | MAPT 2968/4885ALDH1A1 2607/4885HPGD 3695/4885 |
| US-20170095458-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPT 4586/4885ALDH1A1 2834/4885HPGD 2694/4885 |
| US-20200147066-A1 | Heteroaryl Sulfonamides and CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPT 4586/4885ALDH1A1 2834/4885HPGD 2694/4885 |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | MAPT 2968/4885ALDH1A1 2607/4885HPGD 3695/4885 |
| US-20100324093-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | MAPT 2968/4885ALDH1A1 2607/4885HPGD 3695/4885 |
| US-20190167651-A1 | HETEROARYL SULFONAMIDES AND CCR2/CCR9 | CCR2, CCR9, CCR1 | MAPT 4586/4885ALDH1A1 2834/4885HPGD 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.